Form 4: Director Ingram Gains ARWR Stock via RSU Grant

Arrowhead Pharmaceuticals Director Douglas S. Ingram acquired 7,819 shares of common stock through a restricted stock unit grant.

Summary

• Douglas S. Ingram, a Director of Arrowhead Pharmaceuticals, Inc. (ARWR), acquired 7,819 shares of common stock.
• The acquisition was made through a restricted stock unit (RSU) grant with an acquisition price of $0 per share.
• These shares will vest in one installment on the first anniversary of the grant date, which is December 16, 2026, contingent on Mr. Ingram's continued service to the Issuer.
• Following this transaction, Mr. Ingram beneficially owns a total of 46,215 shares of ARWR common stock.

Sentiment

Score: 7

Explanation: The filing indicates a routine equity compensation grant to a director, which is generally positive as it aligns management's interests with shareholders and signals continued commitment. No negative financial or operational news is present, making it a neutral to slightly positive event.

Positives

• Director Ingram's beneficial ownership increased by 7,819 shares, demonstrating continued alignment with shareholder interests.
• The grant of restricted stock units (RSUs) is a common form of equity compensation, aligning management incentives with long-term company performance and retention.

Risks

• The vesting of the 7,819 restricted stock units is subject to Douglas S. Ingram's continued service to Arrowhead Pharmaceuticals, Inc. until December 16, 2026.

Future Outlook

The vesting schedule for the restricted stock units indicates an expectation of Douglas S. Ingram's continued service to the company until at least December 16, 2026, reinforcing long-term commitment.

Industry Context

This is a routine insider transaction for a director at a pharmaceutical company. Equity compensation, such as restricted stock units, is a standard practice in the biotech and pharma sectors to incentivize long-term commitment and align the interests of key personnel with those of shareholders, especially given the long development cycles inherent in the industry.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) to directors is a common practice in the biotechnology and pharmaceutical industry, similar to compensation structures observed at comparable companies like Moderna or Pfizer, aimed at retaining talent and aligning interests.
• A $0 acquisition price for RSUs is standard, reflecting their nature as compensation rather than a market purchase.

Stakeholder Impact

• Shareholders: The transaction increases a director's equity stake, potentially enhancing alignment between management and shareholder interests for long-term value creation.
• Employees: While this specific filing is for a director, standard equity compensation practices can generally contribute to positive employee morale and retention across the organization.

Next Steps

• The 7,819 restricted stock units are scheduled to vest on December 16, 2026, subject to Douglas S. Ingram's continued service.

Key Dates

Recommendation

This Form 4 filing details a routine restricted stock unit grant to an existing director, which is a standard compensation practice aimed at aligning management incentives with long-term shareholder value. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, suggesting that existing positions be maintained based on broader company fundamentals rather than this specific insider transaction.

Keywords

Arrowhead Pharmaceuticals, ARWR, Form 4, Insider Transaction, Restricted Stock Units, Director Compensation, Equity Grant